Literature DB >> 34070748

Risk-Reducing Mastectomy and Reconstruction Following Prophylactic Breast Irradiation: Hope Sustained.

Merav A Ben David1,2, Ella Evron3,4, Adi F Rasco5, Ayelet Shai6,7, Benjamin W Corn4,8.   

Abstract

Risk-reducing mastectomy (RRM) is often advocated for BRCA1/2 mutation carriers who face a heightened lifetime risk of breast cancer. However, many carrier patients seek alternative risk-reducing measures. In a phase II nonrandomized trial, we previously reported that prophylactic irradiation to the contralateral breast among BRCA carriers undergoing breast-conserving treatment significantly reduced subsequent contralateral breast cancer. Herein, we report the outcome of salvage mastectomy and reconstruction in 11 patients that suffered reoccurrences of breast cancer in either the ipsilateral or contralateral breast or elected to have the procedure for risk reduction during the eight-year follow-up period. Patients' satisfaction with the procedure and physicians' assessment of the cosmetic outcome were not inferior for previously irradiated compared to non-irradiated breasts. Although the numbers are small, the results are encouraging and sustain hope in a challenging population. Our findings support continuing research as well as a discussion of risk-reduction alternatives besides mastectomy, including prophylactic breast irradiation, in BRCA1/2 mutation carriers.

Entities:  

Keywords:  BRCA mutation; breast cancer; prophylactic breast irradiation

Year:  2021        PMID: 34070748     DOI: 10.3390/cancers13112694

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  19 in total

1.  Is bilateral radiation an option for BRCA mutation carriers with unilateral breast cancer?

Authors:  Steven A Narod
Journal:  Ann Transl Med       Date:  2019-04

2.  Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.

Authors:  Joseph A Sparano; Robert J Gray; Peter M Ravdin; Della F Makower; Kathleen I Pritchard; Kathy S Albain; Daniel F Hayes; Charles E Geyer; Elizabeth C Dees; Matthew P Goetz; John A Olson; Tracy Lively; Sunil S Badve; Thomas J Saphner; Lynne I Wagner; Timothy J Whelan; Matthew J Ellis; Soonmyung Paik; William C Wood; Maccon M Keane; Henry L Gomez Moreno; Pavan S Reddy; Timothy F Goggins; Ingrid A Mayer; Adam M Brufsky; Deborah L Toppmeyer; Virginia G Kaklamani; Jeffrey L Berenberg; Jeffrey Abrams; George W Sledge
Journal:  N Engl J Med       Date:  2019-06-03       Impact factor: 91.245

3.  Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation.

Authors:  H Meijers-Heijboer; B van Geel; W L van Putten; S C Henzen-Logmans; C Seynaeve; M B Menke-Pluymers; C C Bartels; L C Verhoog; A M van den Ouweland; M F Niermeijer; C T Brekelmans; J G Klijn
Journal:  N Engl J Med       Date:  2001-07-19       Impact factor: 91.245

4.  Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers.

Authors:  L C Hartmann; T A Sellers; D J Schaid; T S Frank; C L Soderberg; D L Sitta; M H Frost; C S Grant; J H Donohue; J E Woods; S K McDonnell; C W Vockley; A Deffenbaugh; F J Couch; R B Jenkins
Journal:  J Natl Cancer Inst       Date:  2001-11-07       Impact factor: 13.506

Review 5.  Radiotherapy in the treatment of hereditary breast cancer.

Authors:  Lori J Pierce; Bruce G Haffty
Journal:  Semin Radiat Oncol       Date:  2011-01       Impact factor: 5.934

6.  Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer.

Authors:  E Warner; W Foulkes; P Goodwin; W Meschino; J Blondal; C Paterson; H Ozcelik; P Goss; D Allingham-Hawkins; N Hamel; L Di Prospero; V Contiga; C Serruya; M Klein; R Moslehi; J Honeyford; A Liede; G Glendon; J S Brunet; S Narod
Journal:  J Natl Cancer Inst       Date:  1999-07-21       Impact factor: 13.506

7.  Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations.

Authors:  L J Pierce; M Strawderman; S A Narod; I Oliviotto; A Eisen; L Dawson; D Gaffney; L J Solin; A Nixon; J Garber; C Berg; C Isaacs; R Heimann; O I Olopade; B Haffty; B L Weber
Journal:  J Clin Oncol       Date:  2000-10-01       Impact factor: 44.544

8.  Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program.

Authors:  Marcia S Brose; Timothy R Rebbeck; Kathleen A Calzone; Jill E Stopfer; Katherine L Nathanson; Barbara L Weber
Journal:  J Natl Cancer Inst       Date:  2002-09-18       Impact factor: 13.506

9.  Validation of a radiosensitivity molecular signature in breast cancer.

Authors:  Steven A Eschrich; William J Fulp; Yudi Pawitan; John A Foekens; Marcel Smid; John W M Martens; Michelle Echevarria; Vidya Kamath; Ji-Hyun Lee; Eleanor E Harris; Jonas Bergh; Javier F Torres-Roca
Journal:  Clin Cancer Res       Date:  2012-07-25       Impact factor: 12.531

10.  Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.

Authors:  Karoline B Kuchenbaecker; John L Hopper; Daniel R Barnes; Kelly-Anne Phillips; Thea M Mooij; Marie-José Roos-Blom; Sarah Jervis; Flora E van Leeuwen; Roger L Milne; Nadine Andrieu; David E Goldgar; Mary Beth Terry; Matti A Rookus; Douglas F Easton; Antonis C Antoniou; Lesley McGuffog; D Gareth Evans; Daniel Barrowdale; Debra Frost; Julian Adlard; Kai-Ren Ong; Louise Izatt; Marc Tischkowitz; Ros Eeles; Rosemarie Davidson; Shirley Hodgson; Steve Ellis; Catherine Nogues; Christine Lasset; Dominique Stoppa-Lyonnet; Jean-Pierre Fricker; Laurence Faivre; Pascaline Berthet; Maartje J Hooning; Lizet E van der Kolk; Carolien M Kets; Muriel A Adank; Esther M John; Wendy K Chung; Irene L Andrulis; Melissa Southey; Mary B Daly; Saundra S Buys; Ana Osorio; Christoph Engel; Karin Kast; Rita K Schmutzler; Trinidad Caldes; Anna Jakubowska; Jacques Simard; Michael L Friedlander; Sue-Anne McLachlan; Eva Machackova; Lenka Foretova; Yen Y Tan; Christian F Singer; Edith Olah; Anne-Marie Gerdes; Brita Arver; Håkan Olsson
Journal:  JAMA       Date:  2017-06-20       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.